Drugs /

ucb6114

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A monoclonal antibody directed against gremlin-1 (GREM1; Drm), with potential antineoplastic activity. Upon administration, anti-gremlin-1 antibody UCB6114 specifically targets and binds to gremlin-1, thereby neutralizing Gremlin-1. This may block the gremlin-1-mediated inhibition of bone morphogenetic protein (BMP) signaling pathways, and may lead to the inhibition of tumor cell growth and proliferation. Gremlin-1, a BMP antagonist that is overexpressed in a variety of cancer cell types, is involved in cancer cell growth and proliferation as well as tissue fibrosis.

Clinical Trials

View Clinical Trials for ucb6114

Ucb6114 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ucb6114, 1 is phase 1/phase 2 (1 open).

Adenocarcinoma of the gastroesophageal junction, bladder urothelial carcinoma, and colorectal adenocarcinoma are the most common diseases being investigated in ucb6114 clinical trials [2].

Drug Details

Synonyms [2]:
anti-grem1 monoclonal antibody ucb6114, anti-gremlin-1 monoclonal antibody ucb6114, ucb 6114, ucb-6114
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
GREM1
NCIT ID [1]:
C173701

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.